StreetInsider.com News Articles

Dogwood Therapeutics enrolls 200 patients in Halneuron pain trial

Mon, 20 Jul 2026 08:30:34 -0400

Dogwood Therapeutics, Inc. (Nasdaq: DWTX) announced it has enrolled the first 200 patients in its ongoing HAL-CINP Phase 2b clinical trial evaluating Halneuron® for chemotherapy-induced neuropathic pain, with top-line data expected in fall 2026.

The randomized trial targets approximately 210 to 240 patients with moderate to severe neuropathic pain caused by prior platinum and/or taxane-based chemotherapy. Participants receive eight subcutaneous doses of Halneuron® or placebo over 14 days and are followed for 28 days. The trial is being conducted at approximately 25 sites in the United States.

The company reported a patient dropout rate of 4.5% in the trial. An independent statistical

Dogwood Therapeutics enrolls 200 patients in Halneuron pain trial

Mon, 20 Jul 2026 08:30:34 -0400

The company reported a patient dropout rate of 4.5% in the trial. An independent statistical

Dogwood Therapeutics enrolls 200 patients in Halneuron pain trial

Mon, 20 Jul 2026 08:30:34 -0400

The company reported a patient dropout rate of 4.5% in the trial. An independent statistical

Dogwood Therapeutics enrolls 200 patients in Halneuron pain trial

Mon, 20 Jul 2026 08:30:34 -0400

The company reported a patient dropout rate of 4.5% in the trial. An independent statistical

Dogwood Enrolls First 200 Patients in Ongoing Halneuron® Phase 2b Chemotherapy Induced Neuropathy Trial; Top-line Data Expected in Fall 2026

Mon, 20 Jul 2026 08:30:00 -0400

ATLANTA, July 20, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), a development-stage biotechnology company developing new medicines to treat pain and neuropathy, today announced it has successfully enrolled the first 200 patients in its ongoing HAL-CINP Phase 2b trial. HAL-CINP remains on track for top-line data readout from the four-week study in the fall of 2026.

“In December, an independent statistical review committee reviewed unblinded patient treatment data from the ongoing Phase 2b trial and concluded that Halneuron® treated patients are demonstrating separation from placebo treated patients in terms of pain improvement

Dogwood Enrolls First 200 Patients in Ongoing Halneuron® Phase 2b Chemotherapy Induced Neuropathy Trial; Top-line Data Expected in Fall 2026

Mon, 20 Jul 2026 08:30:00 -0400

Dogwood Enrolls First 200 Patients in Ongoing Halneuron® Phase 2b Chemotherapy Induced Neuropathy Trial; Top-line Data Expected in Fall 2026

Mon, 20 Jul 2026 08:30:00 -0400

Dogwood Enrolls First 200 Patients in Ongoing Halneuron® Phase 2b Chemotherapy Induced Neuropathy Trial; Top-line Data Expected in Fall 2026

Mon, 20 Jul 2026 08:30:00 -0400

Dogwood Enrolls First 200 Patients in Ongoing Halneuron® Phase 2b Chemotherapy Induced Neuropathy Trial; Top-line Data Expected in Fall 2026

Mon, 20 Jul 2026 08:30:00 -0400

Dogwood Enrolls First 200 Patients in Ongoing Halneuron® Phase 2b Chemotherapy Induced Neuropathy Trial; Top-line Data Expected in Fall 2026

Mon, 20 Jul 2026 08:30:00 -0400

Dogwood Enrolls First 200 Patients in Ongoing Halneuron® Phase 2b Chemotherapy Induced Neuropathy Trial; Top-line Data Expected in Fall 2026

Mon, 20 Jul 2026 08:30:00 -0400

Dogwood Enrolls First 200 Patients in Ongoing Halneuron® Phase 2b Chemotherapy Induced Neuropathy Trial; Top-line Data Expected in Fall 2026

Mon, 20 Jul 2026 08:30:00 -0400

Dogwood Therapeutics names Iain Dukes to lead new advisory board